ArticleFrontiers in oncology2025
Global burden of head and neck cancer: Epidemiological transitions, inequities, and projections to 2050.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluating Effectiveness of mHealth Interventions for Rehabilitation in Patients With Head and Neck Cancer: Systematic Review and Meta-Analysis of Randomized Controlled Trials.JMIR mHealth and uHealth · 2026Pooled it
- Microenvironmental barriers to healing in osteoradionecrosis and opportunities for regenerative intervention.Bioactive materials · 2027Review
- Article
- Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma.BMC cancer · 2026Article
- Subsequent depression in patients with lip and head and neck cancer: a population-based primary care analysis.Clinical oral investigations · 2026Article
- Genetically informed prioritization of immune checkpoint-associated genes in head and neck cancer highlights HGF and AKT1.Functional & integrative genomics · 2026Article
- The emerging landscape for next-generation HNSCC treatment.Trends in pharmacological sciences · 2026Review
- Hospital Length of Stay and Associated Factors in Patients with Oral Cavity Cancer in Germany: A Retrospective Multicenter Analysis of Inpatient Administrative Data.Reports (MDPI) · 2026Article
- Article
- Beyond Restoration: Psychological Health Impact of Prosthodontic Rehabilitation in Head and Neck Cancer Survivors.Annals of neurosciences · 2026Article
- Tumor Biomarkers in Head and Neck Squamous Cell Carcinoma: From Etiology and Pathogenesis to Treatment Response-A Scoping Review.Biomedicines · 2026Review
- Article
- Article
- Propofol in Perioperative Management of Head and Neck Cancer: A Narrative Review of Molecular Mechanisms and Clinical Implications.Current issues in molecular biology · 2026Review
- Conventional vs. 3D-printed complete dentures in an irradiated edentulous patient: a case report with clinical comparison.Medicine and pharmacy reports · 2026Article
- Virtual photon-counting micro-CT platform for simulation of head and neck cancer imaging in mice.Physics in medicine and biology · 2026Article
- Multiparametric MRI for Assessing the Tumor Microenvironment in Head and Neck Cancer: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Xenobiotic Sulforaphane in Head and Neck Cancer: Beyond the Nrf2 Pathway.Journal of xenobiotics · 2026Review
- Digital Pathology in Head and Neck Squamous Cell Carcinoma: Translational Advances and Clinical Integration for Pathologists, Oncologists, and Surgeons.Head and neck pathology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Head and neck cancer (HNC) is the seventh most frequently occurring cancer worldwide. The incidence and mortality of HNC have been demonstrated to significantly impact human health and increase the global health burden. We assessed temporal trends via Estimated Annual Percentage Change (EAPC) across 36 countries (2008-2017). No study has yet focused on the latest epidemiological changes of GLOBOCAN 2022 in HNC and made predictions about the trends to 2050. Objectives: Integrate historical HNC records and project global incidence and mortality trends to 2050 to support region-specific prevention strategies. Methods: Data on HNC cases and deaths including rates for subtypes were gathered from GLOBOCAN 2022 (https://gco.iarc.fr). The age-standardized incidence and mortality rates per 100,000 person-years were calculated by the direct age standardization method based on the Segi-Doll World standard population. We counted EAPC in 36 countries over the last decade (2008-2017). Eight of these countries with different levels of development were also selected to observe in detail their annual trends from 1980 to 2017. Relationship between the Human Development Index (HDI) and the HNC subtypes was examined using linear regression. Conclusion: From 2008 to 2017, both the number of male HNC deaths and cases decreased. However, in 2022, the men's and older people's HNC burden is still heavier. According to the projection, future reductions in overall HNC incidence and mortality are expected to materialize only in the event of a decline in cases and deaths by 2 or 3 percent or more.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.